Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma

Abstract

The tumor microenvironment is complicated and continuously evolving. This study was devoted to the identification of potential prognostic biomarkers based on the tumor microenvironment associated with immunotherapy for melanoma. This study integrates a couple of melanoma single cell and transcriptome sequencing datasets and performs a series of silico analyses as nicely as validation of molecular biology techniques. A core set of immune escape related genes was identified through Lawson et al. and the ImmPort portal. The differential proteins were identified through the cBioPortal database. Regression analysis was used to profile independent prognostic factors. Correlation with the level of immune cell infiltration was evaluated by multiple algorithms. The capacity of LCK to predict response was assessed in two independent immunotherapy cohorts. High LCK expression is associated with better prognosis, high levels of TILs and better clinical staging. Pathway analysis showed that high expression of LCK was significantly associated with activation of multiple tumor pathways as well as immune-related pathways. LCK expression tends to be higher in immunotherapy-responsive patients and those with lower IC50s treated with chemotherapeutic agents. RT-qPCR detected that LCK expression was significantly upregulated in melanoma cell lines. Single-cell transcriptome analysis showed that LCK was specifically highly expressed on T cells. CellChat analysis confirmed that LCK in C2 subpopulations and T cell subpopulations exerted immune promotion between cells by binding to CD8 receptors. In conclusion, LCK is a reliable biomarker for melanoma and will contribute to its immunotherapy.

Lipid–Polymer Hybrid Nanoparticles with Both PD-L1 Knockdown and Mild Photothermal Effect for Tumor Photothermal Immunotherapy

“…T cells are important effectors for the immune system to exert antitumor effects. Cytotoxic T lymphocytes, also known as CD8 + T cells, play a crucial role in the antitumor cellular immune response. , CD4 + T cells have various subtypes, can secrete cytokines, and have regulatory effects on antitumor immunity. Some clinical studies have also found that CD4 + T cells can secrete key molecules related to cell lysis particles, which have direct cytotoxic effects .…”

Development and validation of a prognostic model for mitophagy-related genes in colon adenocarcinoma: A study based on TCGA and GEO databases

“…Then this study evaluated the response of COAD patients to immunotherapy. It has been reported that the immune system plays an important role in the progression and treatment of cancer, and the presence of tumor immune escape protects tumor cells from the attack of the immune system [ 36 , 37 ]. Differentiation clusters, as markers of immune cells, such as CTLA-4, CD25, and PD-1, have been identified as potential immunotherapy targets for malignant tumors in recent years [ 38 , 39 ].…”

APOB is a potential prognostic biomarker in hepatocellular carcinoma

“…In this context, immunotherapy for cancer treatment has been gaining increased attention [ 12 – 16 ]. Several researchers have discovered that blockers of cytotoxic T lymphocyte-associated antigen 4, programmed cell death-ligand 1, and programmed cell death-1 elicit anti-cancer effects on HCC cells [ 17 – 19 ].…”